logo-loader
viewAlgernon Pharmaceuticals Inc.

Full interview: Algernon Pharmaceuticals updates Phase 2 human testing of Ifenprodil for COVID-19

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joins Steve Darling from Proactive Vancouver to provide an update that a protocol is planned for a  physician initiated phase 2 clinical study of NP-120 for COVID-19 infected patients in South Korea.

Moreau telling Proactive how they are fast tracked for this trial and what the next steps will be.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.325 CAD

CSE:AGN
Market: CSE
Market Cap: $29.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Fax Capital CEO talks investment and aligning with the right...

Fax Capital (TSE: FXC-) CEO Blair Driscoll joined Steve Darling from Proactive Vancouver to discuss the investment holding company that intends to invest in approximately 10 to 15 high-quality small-cap public and private businesses located primarily in Canada. Driscoll tells Proactive why...

5 hours, 53 minutes ago

2 min read